Terns files 8-K on TERN-601 Phase 2 12-week topline data

Rhea-AI Filing Summary

Terns Pharmaceuticals reported that it issued a press release announcing topline 12-week results from its Phase 2 trial of TERN-601, a novel, once-daily, oral GLP-1 receptor agonist being studied as a potential treatment for obesity.

The press release is furnished as Exhibit 99.1 and incorporated by reference. Terns’ common stock trades on the Nasdaq Global Select Market under the symbol TERN.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 10/21/2025 - 05:40 PM Learn about SEC filing dates

false 0001831363 0001831363 2025-10-21 2025-10-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2025

Terns Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39926		98-1448275
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1065 East Hillsdale Blvd. Suite 100 Foster City, California		94404
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 525-5535

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		TERN		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 21, 2025, Terns Pharmaceuticals, Inc. issued a press release announcing topline 12-week results from its Phase 2 trial of TERN-601, a novel, once-daily, oral GLP-1 receptor agonist, as a potential treatment for obesity. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, issued by Terns Pharmaceuticals, Inc. on October 21, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				TERNS PHARMACEUTICALS, INC.
Date: October 21, 2025				By:		/s/ Caryn McDowell
						Caryn McDowell
						Chief Legal Officer and Corporate Secretary

FAQ

What did Terns Pharmaceuticals (TERN) announce?

The company announced topline 12-week results from a Phase 2 trial of TERN-601 and furnished a press release as Exhibit 99.1.

What is TERN-601 according to the filing?

TERN-601 is described as a novel, once-daily, oral GLP-1 receptor agonist being evaluated as a potential treatment for obesity.

What stage of development is TERN-601 in?

It is in a Phase 2 clinical trial with topline 12-week results announced.

Where can investors find the detailed results?

Details are in the press release filed as Exhibit 99.1, incorporated by reference.

What exchange and ticker does Terns trade under?

Terns’ common stock trades on the Nasdaq Global Select Market under the symbol TERN.

What indication is TERN-601 targeting?

The trial evaluates TERN-601 as a potential treatment for obesity.